Clinical Trials
65 trialsA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
DP-04
AstraZeneca
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
ADVICE
Filamon LTD
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
SCORE
Natera, Inc.
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
PRESERVE-001
OncoC4, Inc.
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
PREFER
Labcorp Corporation of America Holdings, Inc
ROOT
Taproot Health
IVY
Eli Lilly and Company
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
QUANTUM
VitaMed Research LLC
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Vector Vitale LLC
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Convalife (Shanghai) Co., Ltd.
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Namida Lab
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
DUET-4
Xencor, Inc.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
DUET-2
Xencor, Inc.
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
LiPlaCis
Allarity Therapeutics
Safety Study of MGA271 in Refractory Cancer
MacroGenics
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
PIONEER
SpeciCare
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene